SCHEDULE: RA Capital Discloses 9.9% Stake in Edgewise Therapeutics

RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in Edgewise Therapeutics, Inc., totaling 10,428,437 shares of common stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have reported beneficial ownership of 10,428,437 shares of Edgewise Therapeutics, Inc. common stock.
• This represents 9.9% of the issuer's outstanding common stock, based on 105,345,708 shares outstanding as of July 31, 2025, as reported in the Issuer's Quarterly Report on 10-Q.
• The shares are directly held by RA Capital Healthcare Fund, L.P.
• RA Capital Management, L.P. serves as the investment adviser for the Fund and holds shared voting and dispositive power over these securities.
• Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital, and may be deemed beneficial owners.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.9% passive stake by a reputable healthcare-focused investment firm like RA Capital Management is generally a positive signal, indicating institutional confidence in Edgewise Therapeutics. However, as a passive investment, it does not imply active involvement in management or a direct endorsement of immediate operational performance.

Positives

• A significant institutional investor, RA Capital Management, has taken a substantial 9.9% stake in Edgewise Therapeutics, indicating confidence in the company's future prospects.
• RA Capital is a well-known healthcare-focused investment firm, suggesting a strategic investment in the biotechnology sector.

Risks

• The filing does not explicitly mention risks related to Edgewise Therapeutics' operations or financial health; it is a disclosure of ownership.
• Investment in a single company, even by a sophisticated investor, carries inherent market and company-specific risks.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain specific forward-looking statements or guidance regarding Edgewise Therapeutics' future performance or RA Capital's investment strategy beyond the passive nature of the stake.

Management Comments

• The filing includes a certification by Peter Kolchinsky, on behalf of RA Capital Management, L.P. and himself, and by Rajeev Shah, stating that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology sector, specifically in companies like Edgewise Therapeutics. RA Capital Management is a prominent healthcare-focused investment firm, and their significant stake suggests a belief in the long-term potential of Edgewise Therapeutics' pipeline or market position within the biotech industry.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by a passive institutional investor. It does not contain operational or financial results that would allow for a direct comparison to industry benchmarks or specific comparable companies or projects.
• The 9.9% stake is a substantial position for an institutional investor in a public company, reflecting a significant commitment.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a substantial stake may instill confidence and potentially attract further institutional interest, positively impacting shareholder sentiment.
• Company Management: The presence of a large, passive institutional investor like RA Capital may provide a level of stability and validation for the company's strategic direction, though without active involvement.

Next Steps

• The filing does not outline any specific future actions, events, or milestones for Edgewise Therapeutics or RA Capital Management beyond the ongoing passive investment.

Key Dates

Recommendation

The filing indicates a significant passive stake by a reputable institutional investor, RA Capital Management, which can be seen as a positive signal of long-term confidence in Edgewise Therapeutics. However, as a Schedule 13G, it does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. The investment is passive, meaning RA Capital is not seeking to influence control. Investors should 'hold' and monitor future company performance and any changes in RA Capital's position or other fundamental developments.

Keywords

Edgewise Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Institutional Investor, EWTX, Peter Kolchinsky, Rajeev Shah